New model aims to predict kidney risk from chemo drug
NCT ID NCT07406230
First seen Feb 18, 2026 · Last updated May 10, 2026 · Updated 11 times
Summary
This study looks at 50 adults with primary central nervous system lymphoma who are receiving high-dose methotrexate. The goal is to see if measuring the drug early in the blood can predict later kidney problems, so doctors can act faster to prevent harm. It is an observational study that does not offer a new treatment, but aims to improve safety monitoring.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Assistance Publique - Hôpitaux de Marseille
Marseille, 13005, France
Contact
Contact
Conditions
Explore the condition pages connected to this study.